105 related articles for article (PubMed ID: 1468560)
1. Inhibition of epidermal growth factor receptor functions by tyrosine kinase inhibitors in NIH3T3 cells.
Umezawa K; Sugata D; Yamashita K; Johtoh N; Shibuya M
FEBS Lett; 1992 Dec; 314(3):289-92. PubMed ID: 1468560
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors.
Umezawa K; Hori T; Tajima H; Imoto M; Isshiki K; Takeuchi T
FEBS Lett; 1990 Jan; 260(2):198-200. PubMed ID: 2298299
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Abelson oncogene function by erbstatin analogues.
Kawada M; Tawara J; Tsuji T; Honma Y; Hozumi M; Wang JY; Umezawa K
Drugs Exp Clin Res; 1993; 19(6):235-41. PubMed ID: 8013266
[TBL] [Abstract][Full Text] [Related]
4. Induction of morphological change by tyrosine kinase inhibitors in Rous sarcoma virus-transformed rat kidney cells.
Umezawa K; Tanaka K; Hori T; Abe S; Sekizawa R; Imoto M
FEBS Lett; 1991 Feb; 279(1):132-6. PubMed ID: 1704855
[TBL] [Abstract][Full Text] [Related]
5. Inhibition kinetics and selectivity of the tyrosine kinase inhibitor erbstatin and a pyridone-based analogue.
Hsu CY; Jacoski MV; Maguire MP; Spada AP; Zilberstein A
Biochem Pharmacol; 1992 Jun; 43(11):2471-7. PubMed ID: 1319162
[TBL] [Abstract][Full Text] [Related]
6. Isolation of a novel substrate-competitive tyrosine kinase inhibitor, desmal, from the plant Desmos chinensis.
Kakeya H; Imoto M; Tabata Y; Iwami J; Matsumoto H; Nakamura K; Koyano T; Tadano K; Umezawa K
FEBS Lett; 1993 Apr; 320(2):169-72. PubMed ID: 8458434
[TBL] [Abstract][Full Text] [Related]
7. Limited selectivity of a synthetic erbstatin derivative for tyrosine kinase and cell growth inhibition.
Treuner M; Böhmer FD; Schulze W; Petuchov SP; Grosse R
Biochem Int; 1992 Mar; 26(4):617-25. PubMed ID: 1319149
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of serum-induced M-phase progression by a tyrosine kinase inhibitor, erbstatin.
Sugata D; Yamashita K; Umezawa K
Biochem Biophys Res Commun; 1993 Jul; 194(1):239-45. PubMed ID: 8333839
[TBL] [Abstract][Full Text] [Related]
9. The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition.
Stanwell C; Burke TR; Yuspa SH
Cancer Res; 1995 Nov; 55(21):4950-6. PubMed ID: 7585535
[TBL] [Abstract][Full Text] [Related]
10. Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor/receptor gene expression in human gastric carcinoma cells.
Takekura N; Yasui W; Kyo E; Yoshida K; Kameda T; Kitadai Y; Abe K; Umezawa K; Tahara E
Int J Cancer; 1991 Apr; 47(6):938-42. PubMed ID: 1849125
[TBL] [Abstract][Full Text] [Related]
11. The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase.
El-Zarruk AA; van den Berg HW
Cancer Lett; 1999 Aug; 142(2):185-93. PubMed ID: 10463775
[TBL] [Abstract][Full Text] [Related]
12. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.
Fry DW; Kraker AJ; McMichael A; Ambroso LA; Nelson JM; Leopold WR; Connors RW; Bridges AJ
Science; 1994 Aug; 265(5175):1093-5. PubMed ID: 8066447
[TBL] [Abstract][Full Text] [Related]
13. Genistein and erbstatin inhibition of normal mammary epithelial cell proliferation is associated with EGF-receptor down-regulation.
McIntyre BS; Sylvester PW
Cell Prolif; 1998 Feb; 31(1):35-46. PubMed ID: 9666817
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EGF-induced cytoskeletal change in A431 cells by inhibitors of phosphatidylinositol turnover.
Johtoh N; Umezawa K
Drugs Exp Clin Res; 1992; 18(1):1-7. PubMed ID: 1600863
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of EGF-induced phospholipase C activation in A431 cells by erbstatin, a tyrosine kinase inhibitor.
Imoto M; Shimura N; Ui H; Umezawa K
Biochem Biophys Res Commun; 1990 Nov; 173(1):208-11. PubMed ID: 2256916
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors inhibit multiple steps of the cell cycle of vascular smooth muscle cells.
Shimokado K; Umezawa K; Ogata J
Exp Cell Res; 1995 Oct; 220(2):266-73. PubMed ID: 7556433
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide reversibly inhibits the epidermal growth factor receptor tyrosine kinase.
Estrada C; Gómez C; Martín-Nieto J; De Frutos T; Jiménez A; Villalobo A
Biochem J; 1997 Sep; 326 ( Pt 2)(Pt 2):369-76. PubMed ID: 9291107
[TBL] [Abstract][Full Text] [Related]
18. Kinetic studies of tyrosine kinase inhibition by erbstatin.
Imoto M; Umezawa K; Isshiki K; Kunimoto S; Sawa T; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1987 Oct; 40(10):1471-3. PubMed ID: 3680017
[No Abstract] [Full Text] [Related]
19. Inhibition of tyrosine kinase activity decreases expression of surfactant protein A in a human lung adenocarcinoma cell line independent of epidermal growth factor receptor.
Klein JM; McCarthy TA
Biochim Biophys Acta; 1997 Mar; 1355(3):218-30. PubMed ID: 9060993
[TBL] [Abstract][Full Text] [Related]
20. Use of erbstatin as protein-tyrosine kinase inhibitor.
Umezawa K; Imoto M
Methods Enzymol; 1991; 201():379-85. PubMed ID: 1658555
[No Abstract] [Full Text] [Related]
[Next] [New Search]
